Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group

被引：5

作者：

Fazio, Francesca ^{[1
]}

Franceschini, Luca ^{[2
]}

Tomarchio, Valeria ^{[3
]}

Rago, Angela ^{[4
]}

Garzia, Maria Grazia ^{[5
]}

Cupelli, Luca ^{[6
]}

Bongarzoni, Velia ^{[7
]}

Andriani, Alessandro ^{[8
]}

Gumenyuk, Svitlana ^{[9
]}

Tafuri, Agostino ^{[10
]}

Siniscalchi, Agostina ^{[11
]}

Piciocchi, Alfonso ^{[12
]}

De Fabritiis, Paolo ^{[13
]}

De Rosa, Luca ^{[14
]}

di Toritto, Tommaso Caravita ^{[15
]}

Annibali, Ombretta ^{[16
]}

Cantonetti, Maria ^{[17
]}

Petrucci, Maria Teresa ^{[1
]}

机构：

[1] Sapienza Univ Rome, Dept Translat & Precis Med Hematol, Azienda Policlin Umberto 1, Rome, Italy

[2] Transplant Network, Hematol Stem Cell Transplant Unit, Rome, Italy

[3] Univ Campus Biomed, Dept Haematol, Rome, Italy

[4] ASL RMA, UOSD Ematologia Asl Roma 1, Rome, Italy

[5] San Camillo Forlanini Hosp, Dept Hematol, Hematol, Rome, Italy

[6] Osped St Eugenio, Hematol, Dept Hematol, Rome, Italy

[7] San Giovanni Addolorata Hosp, Dept Hematol, Rome, Italy

[8] Osped Fabrizio Spaziani, Dept Hematol, Rome, Italy

[9] Regina Elena Inst Canc Res, Haematol & Stem Cell Transplant, Rome, Italy

[10] Azienda Osped St Andrea, Rome, Italy

[11] S Eugenio Hosp, Inst Haematol, Rome, Italy

[12] Italian Grp Adult Hematol Dis GIMEMA, Ctr Data, Rome, Italy

[13] Osped St Eugenio, Dept Haematol, Rome, Italy

[14] Azienda Osped San Camillo Forlanini, Hematol & Bone Marrow Transplantat Unit, Rome, Italy

[15] ASL Roma 1, Dept Hematol, Rome, Italy

[16] Campus Biomed Univ Rome, Dept Haematol, Rome, Italy

[17] Univ Tor Vergata, Chair Hematol, Rome, Italy

来源：

EJHAEM | 2022年 / 3卷 / 01期

关键词：

immunotherapy; multiple myeloma; relapsed refractory; PLUS LENALIDOMIDE; MONOTHERAPY; CD38; LYMPHOCYTES; EFFICACY; CELLS;

D O I：

10.1002/jha2.359

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab is a human IgGK monoclonal antibody targeting CD38 with tumor activity associated with immunomodulatory mechanism. In combination with standard of care regimens, including bortezomib (Vd) or lenalidomide (Rd), daratumumab prolonged progression-free survival (PFS) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and in new diagnosis MM. We report the data of the MM GIMEMA Lazio group in 171 heavily treated pts who received daratumumab, lenalidomide and dexamethasone (DRd) or daratumumab, velcade and dexamethasone (DVd). The overall response rate was 80%, and the overall survival (OS) and PFS were 84% and 77%, respectively. In addition, pts treated with DRd showed a better median PFS compared to pts treated with DVd, at 12 and 24 months, respectively. The most common hematologic treatment-emergent adverse events (TAEs) were neutropenia, thrombocytopenia, and anemia. The most common nonhematologic TAEs were peripheral sensory neuropathy and infections. Our data confirmed that DRd or DVd therapy is effective and safe in RRMM pts, and our real-life analysis could support the physicians regarding the choice of optimal therapy in this setting of pts.

引用

页码：121 / 128

页数：8

共 50 条

[31] EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF CASTOR
Weisel, K.
Lentzsch, S.
Mateos, M. V.
Hungria, V.
Munder, M.
Nooka, A.
Mark, T.
Quach, H.
Scott, E. C.
Lee, J. -J.
Sonneveld, P.
Casneuf, T.
Chiu, C.
Qin, X.
Amin, H.
Thiyagarajah, P.
Schecter, J. M.
Qi, M.
Spencer, A.
HAEMATOLOGICA, 2017, 102 : 168 - 169
[32] Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor
Spencer, Andrew
Hungria, Vania T. M.
Mateos, Maria-Victoria
Nooka, Ajay
Estell, Jane
Barreto, Wolney G.
Corradini, Paolo
Min, Chang-Ki
Medvedova, Eva
Thiyagarajah, Piruntha
Deraedt, William
Chiu, Christopher
Schecter, Jordan
Weisel, Katja C.
BLOOD, 2017, 130
[33] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
Shinsuke Iida
Tatsuo Ichinohe
Atsushi Shinagawa
Kenshi Suzuki
Naoki Takezako
Masayuki Aoki
International Journal of Hematology, 2018, 107 : 460 - 467
[34] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
Iida, Shinsuke
Ichinohe, Tatsuo
Shinagawa, Atsushi
Suzuki, Kenshi
Takezako, Naoki
Aoki, Masayuki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (04) : 460 - 467
[35] Bortezomib asociated to dexamethasone in patients with relapsed/refractory multiple myeloma
de la O, G. M. Maria
Garcia-Delgado, R.
Cuesta, M. A.
Garrido, P.
Dominguez, B.
Hernandez, F.
Galan, M.
Sanchez, A.
Garcia-Sanchez, R.
Lopez, E.
Perez, E.
Bailen, A.
Heiniger, A. I.
Ramirez, G.
Garcia, A.
Jurado, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 482 - 483
[36] A REAL-LIFE STUDY OF DARATUMUMAB-BORTEZOMIB-DEXAMETHASONE (DVD) IN LENALIDOMIDE EXPOSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REPORT FROM THE MYELOMA TRIVENETO WORKING GROUP
Barila, G.
Quaglia, F. M.
Furlan, A.
Pescosta, N.
Patriarca, F.
Pascarella, A.
De March, E.
Lico, A.
Sartori, R.
De Sabbata, G.
Marcon, C.
Vedovato, S.
Wieczoreck, M.
Nappi, D.
De Marchi, R.
Gherlinzoni, F.
Krampera, M.
Semenzato, G.
Zambello, R.
HAEMATOLOGICA, 2021, 106 (10) : 60 - 60
[37] Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
Weisel, K.
Palumbo, A.
Chanan-Khan, A.
Nooka, A. K.
Spicka, I.
Masszi, T.
Beksac, M.
Hungria, V.
Munder, M.
Mateos, M-V.
Mark, T. M.
Spencer, A.
Qi, M.
Schecter, J.
Amin, H.
Qin, X.
Deraedt, W.
Ahmadi, T.
Sonneveld, P.
ANNALS OF ONCOLOGY, 2016, 27
[38] Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
Wong, Xin Yi
Chng, Wee Joo
Aziz, Mohamed Ismail Abdul
Ng, Kwong
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (02) : 207 - 215
[39] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Dimopoulos, M. A.
Oriol, A.
Nahi, H.
San-Miguel, J.
Bahlis, N. J.
Usmani, S. Z.
Rabin, N.
Orlowski, R. Z.
Komarnicki, M.
Suzuki, K.
Plesner, T.
Yoon, S. -S.
Ben Yehuda, D.
Richardson, P. G.
Goldschmidt, H.
Reece, D.
Lisby, S.
Khokhar, N. Z.
O'Rourke, L.
Chiu, C.
Qin, X.
Guckert, M.
Ahmadi, T.
Moreau, P.
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14): : 1319 - 1331
[40] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Dimopoulos, Meletios
Spencer, Andrew
Attal, Michael
Prince, H. Miles
Harousseau, Jean-Luc
Dmoszynska, Anna
San Miguel, Jesus
Hellmann, Andrzej
Facon, Thierry
Foa, Robin
Corso, Alessandro
Masliak, Zvenyslava
Olesnyckyj, Marta
Yu, Zhinuan
Patin, John
Zeldis, Jerome B.
Knight, Robert D.
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21): : 2123 - 2132

← 1 2 3 4 5 →